Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo

Contact: Michelle Linn
Linnden Communications

Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:

(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
Cached News: